Memantine: a comprehensive review of safety and efficacy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor. It is now approved only for treatment of moderate-to-severe Alzheimer's disease (AD). However, as a growing body of evidence indicates that disturbed glutamate neurotransmission may be central to the pathophysiology of such conditions as obesity, schizophrenia, depression, substance abuse, pain disorders and glaucoma, clinical trials have explored the role of memantine in these and other disorders. OBJECTIVE: To provide a comprehensive review of the safety and efficacy of memantine across the range of clinical applications in which it has been studied. METHODS: A search was done on Pubmed using keyword 'memantine' to identify clinical trials of memantine. RESULTS/CONCLUSION: At present, clinical trial evidence supports the use of memantine in only moderate-to-severe AD. Preliminary studies suggest benefit in frontotemporal dementia, alcohol dependence, post-traumatic stress disorder, headache and obesity, but rigorous clinical trials are needed to confirm these results. Available data indicate that across a range of clinical applications, memantine is a safe and well-tolerated drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · cited 2×
“1 Vascular dementia In two double-blind placebo-controlled trials, MMM300 [21] and MMM500 [22] , memantine had a beneficial effect on cognition but not global status, and thus the cognitive benefit was of questionable clinical significance.”
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Self-citationA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Morphologic diagnosis of “vascular dementia” — A critical update
Jellinger, K. A. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.03.006 · Cited by 150 · cited 1×
“However, as lacunar infarctions and white matter disease themselves probably represent different pathophysiologic processes and the clinical significance of white matter lesions remains unclear, the subgroups used in the post hoc analysis may be regarded as controversial [24] .”
Mechanisms of action of current and potential pharmacotherapies of obsessive–compulsive disorder
El Mansari, M., & Blier, P. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.005 · Cited by 142 · cited 1×
“In addition, the neurosurgical procedure of capsulotomy, reserved for the most severe, treatment refractory cases of OCD, targets the efferent glutamatergic axons from the orbitofrontal cortex to the caudate [47] .”
Cited by
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Memantine is approved by the FDA and other regulatory agencies for the treatment of moderate-severity Alzheimer’s disease and is widely used for this indication (Kavirajan, 2009).”
BackgroundInfluentialNanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca-Santos, B., Chorilli, M., & Palmira Daflon Gremião, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 308
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“Memantine is generally well tolerated even in the elderly population and has a relatively low propensity for drug-drug interactions [76].”
BackgroundAmidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Zheng, X., Li, W., Xiang, Q., Wang, Y., Qu, T., Fang, W., & Yang, H. (2023) · ACS Omega · doi:10.1021/acsomega.3c06250 · Cited by 10
Metadata
- Authors
- Kavirajan, H.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2008-11-12
- Volume
- 8
- Issue
- 1
- Pages
- 89-109
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W1976940440
- Cited by
- 84
- References
- 9
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memantine: a comprehensive review of safety and efficacy. https://app.cochat.ai/papers/10.1517/14740330802528420
- The paper
- Kavirajan, H. (2009). Memantine: a comprehensive review of safety and efficacy. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740330802528420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.